Sage Bionetworks to Model Cancer Pathway Data for AstraZeneca

The collaboration is the third that Sage has announced with a major pharmaceutical firm, adding to existing agreements with Merck and Pfizer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.